XTX-202 is a fusion protein commercialized by Xilio Therapeutics, with a leading Phase II program in Metastatic Renal Cell Carcinoma. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of XTX-202’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for XTX-202 is expected to reach an annual total of $95 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
XTX-202 is under development for the treatment of advanced solid tumors including metastatic renal cell carcinoma, ovarian cancer, non-small cell lung cancer, squamous cell skin carcinoma and metastatic melanoma. The drug candidate targets IL2 cytokine. The drug candidates are based on Aklusion and Switchblade platform technology.
Xilio Therapeutics Overview
Xilio Therapeutics is a biotechnology company that discovers and develops immuno-oncology therapeutics for the treatment of lung cancer. Xilio Therapeutics is headquartered in Waltham, Massachusetts, the US.
The operating loss of the company was US$75 million in FY2021, compared to an operating loss of US$54.6 million in FY2020. The net loss of the company was US$75.8 million in FY2021, compared to a net loss of US$55.2 million in FY2020.
For a complete picture of XTX-202’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.